Compare Nasdaq Inc (NDAQ) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Tenet Healthcare Corporation — how do they compare? Nasdaq Inc trades at $92.6 (market cap $51.63B), while Tenet Healthcare Corporation trades at $260 (market cap $20.98B). The key difference: Nasdaq Inc is far larger — about 2.5× Tenet Healthcare Corporation's market cap, and Nasdaq Inc pays a 1.26% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 125 Days and Tenet Healthcare Corporation for 15 Days on average.
| NDAQ | THC | |
|---|---|---|
Market Cap | $51.63B | $20.98B |
Volume | 2,668,175 | 428,008 |
Sector | Financials | Health |
52-Week High | $100.98 | $280.77 |
52-Week Low | $76.85 | $161.37 |
Typical Hold Time | 125 Days | 15 Days |
Enterprise Value | $58.09B | $32.06B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $91.93, down 0.37% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $8.26 billion and net income of $1.79 billion, yielding a net margin of 21.64%. Recent news highlights growth in its Financial Technology segment, including AI enhancements to the Calypso platform and new client adoptions like HSBC.
The outlook is positive given analyst consensus with a $110.71 price target and 61% buy ratings, though near-term technical weakness and high valuation ratios pose risks. Key catalysts include continued tech adoption and cross-selling, while risks involve market volatility and execution challenges in a competitive landscape.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (ROE 53.31%, net margin 9.9%). Recent news highlights strong cash flow supporting capital returns and upcoming Q3 2026 results on October 29. Valuation appears reasonable with P/E of 10.07 and EV/EBITDA of 5.75.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and 7% upside to consensus target of $283.36. Key catalysts include sustained earnings momentum and efficient capital allocation. Risks include surgical volume pressures and cash flow sustainability concerns amid aggressive buybacks. The stock's current technical setup near pivot point $259 suggests balanced risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
